U.S. Pet Health Sales
Join us as we enter our next era of innovation and growth.
Join us as we enter our next era of innovation and growth.
A ground-breaking and first-of-its-kind solution to treating canine parvovirus, one of the most contagious and deadliest diseases a dog can face.
The first-of-its kind oral tablet aimed at treating feline diabetes.
The first oral treatment for anemia in cats with chronic kidney disease.
At Elanco, we are always looking for new solutions to help address unmet needs for the world’s animals. Our latest innovative product, the Canine Parvovirus Monoclonal Antibody, is a great example of our team’s commitment to treating devastating and chronic diseases. Watch as our President & CEO, Jeff Simmons, explains how we’re addressing animals’ unmet needs through innovation.
We commit to pursuing our four behavioral pillars each and every day: Involve, Deliver, Own, Innovate.
We act with humility as One Elanco, collaborating for the best outcomes for the entire company.
We focus on the essential, build mastery, and diligently deliver on our commitments to our colleagues, customers and shareholders.
Innovation is a mindset that drives continuous improvement of our processes, products and services.
We're accountable and empowered. We ask questions and raise concerns. We're fully invested in Elanco's success.
Get to know Elanco and our perspective on animal health by exploring more articles below.
Our people’s desire to make a difference drives innovation, challenges status quo, and helps tackle tough issues as a team.
Learn why we're a leading provider of innovative solutions that protect and enhance animal health.
Read About ElancoElanco's Healthy Purpose, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2024 Elanco or its affiliates.